Press Release

Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors

August 7, 2019 at 8:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 7, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. Mr. Cole has more than 20 years of pharmaceutical business development experience and is currently the Chief Business Officer and Head of Corporate Development at Jounce Therapeutics.

“We are pleased to have Hugh join us on the Board,” said Ken Bate, Chairman of Catabasis’ Board of Directors. “His extensive experience in business development and commercial strategy will be an asset to Catabasis as we prepare to become a commercial rare disease organization following the completion of the Phase 3 clinical trial of edasalonexent in Duchenne muscular dystrophy.”

“I am excited to join the Board at Catabasis and look forward to contributing to the strategy to ensure that the full potential of edasalonexent is achieved. This is an exciting time at Catabasis as the commercialization planning work is underway for the anticipated future launch of edasalonexent, a therapy that has the potential to benefit a broad range of patients affected by Duchenne, regardless of mutation type,” said Hugh M. Cole.

Prior to Jounce Therapeutics, Mr. Cole served as Chief Business Officer at ARIAD Pharmaceuticals from 2014 to 2017 and was previously at Shire Pharmaceuticals as Senior Vice President, Strategic Planning and Program Management from 2012 to 2014, Global Franchise Leader from 2009 to 2012, and head of Business Development for Shire’s rare disease business from 2007 to 2009. Mr. Cole holds an AB from Harvard University and an MBA from the Wharton School at the University of Pennsylvania.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 trial, please visit

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the potential commercial launch of edasalonexent, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Source: Catabasis Pharmaceuticals, Inc.

Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971